Literature DB >> 30688360

Obstetric management, tests, and technologies that impact childhood development.

Christopher M Novak1, Ernest M Graham1,2.   

Abstract

Childhood brain development begins before birth, and obstetric management, tests, and technologies designed to diagnose and treat fetal conditions can have an impact on development. Preconception counseling for maternal diabetes and hypertension affect the risk of fetal congenital anomalies and growth restriction. Patients with risk factors for pre-existing maternal diabetes are offered early diabetic screening because earlier diagnosis and treatment can decrease the risk of fetal and neonatal complications. Screening for chromosomal abnormalities in the first or second trimester is offered to all females regardless of age. Cell-free fetal DNA screening can be used to test for fetal genetic abnormalities as early as 9 weeks of gestation with results available in 10 days. Ultrasound performed around 20 weeks' gestation can identify the 3% of fetuses that have a major congenital malformation. Fetal magnetic resonance imaging can be used to better assess fetal central nervous system abnormalities when neurosonography is inconclusive. Doppler ultrasound can be used to assess blood flow in the umbilical artery and fetal middle cerebral artery to aid in the management of the growth-restricted fetus. In summary, diagnosis and treatment of maternal and fetal conditions from the preconception period throughout pregnancy are important for optimizing fetal health and provide the best opportunity for optimal child development. WHAT THIS PAPER ADDS: Cell-free fetal DNA screening can identify fetal genetic abnormalities as early as 9 weeks' gestation. Ultrasound performed around 20 weeks' gestation can detect major fetal congenital malformations. Fetal magnetic resonance imaging can aid neurosonography in the assessment of fetal central nervous system abnormalities. Doppler ultrasound to assess fetal blood flow is used to successfully manage the growth-restricted fetus.
© 2019 Mac Keith Press.

Entities:  

Mesh:

Year:  2019        PMID: 30688360      PMCID: PMC6661226          DOI: 10.1111/dmcn.14160

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  33 in total

1.  Neonatal Glycemia and Neurodevelopmental Outcomes at 2 Years.

Authors:  Christopher J D McKinlay; Jane M Alsweiler; Judith M Ansell; Nicola S Anstice; J Geoffrey Chase; Gregory D Gamble; Deborah L Harris; Robert J Jacobs; Yannan Jiang; Nabin Paudel; Matthew Signal; Benjamin Thompson; Trecia A Wouldes; Tzu-Ying Yu; Jane E Harding
Journal:  N Engl J Med       Date:  2015-10-15       Impact factor: 91.245

2.  Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years.

Authors:  Christopher J D McKinlay; Jane M Alsweiler; Nicola S Anstice; Nataliia Burakevych; Arijit Chakraborty; J Geoffrey Chase; Gregory D Gamble; Deborah L Harris; Robert J Jacobs; Yannan Jiang; Nabin Paudel; Ryan J San Diego; Benjamin Thompson; Trecia A Wouldes; Jane E Harding
Journal:  JAMA Pediatr       Date:  2017-10-01       Impact factor: 16.193

3.  Finding Middle Ground in Constructing a Clinically Useful Expanded Carrier Screening Panel.

Authors:  Blair Stevens; Nevena Krstic; Malorie Jones; Lauren Murphy; Jennifer Hoskovec
Journal:  Obstet Gynecol       Date:  2017-08       Impact factor: 7.661

4.  Risk of ultrasound-detected neonatal brain abnormalities in intrauterine growth-restricted fetuses born between 28 and 34 weeks' gestation: relationship with gestational age at birth and fetal Doppler parameters.

Authors:  R Cruz-Martinez; V Tenorio; N Padilla; F Crispi; F Figueras; E Gratacos
Journal:  Ultrasound Obstet Gynecol       Date:  2015-08-25       Impact factor: 7.299

5.  Committee Opinion No. 691 Summary: Carrier Screening for Genetic Conditions.

Authors: 
Journal:  Obstet Gynecol       Date:  2017-03       Impact factor: 7.661

6.  Practice Bulletin No. 180: Gestational Diabetes Mellitus.

Authors: 
Journal:  Obstet Gynecol       Date:  2017-07       Impact factor: 7.661

7.  Increased nuchal translucency thickness and risk of neurodevelopmental disorders.

Authors:  S G Hellmuth; L H Pedersen; C B Miltoft; O B Petersen; S Kjaergaard; C Ekelund; A Tabor
Journal:  Ultrasound Obstet Gynecol       Date:  2017-04-05       Impact factor: 7.299

Review 8.  The incidence of congenital heart disease.

Authors:  Julien I E Hoffman; Samuel Kaplan
Journal:  J Am Coll Cardiol       Date:  2002-06-19       Impact factor: 24.094

9.  Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association.

Authors:  Bradley S Marino; Paul H Lipkin; Jane W Newburger; Georgina Peacock; Marsha Gerdes; J William Gaynor; Kathleen A Mussatto; Karen Uzark; Caren S Goldberg; Walter H Johnson; Jennifer Li; Sabrina E Smith; David C Bellinger; William T Mahle
Journal:  Circulation       Date:  2012-07-30       Impact factor: 29.690

10.  Time Costs for Genetic Counseling in Preconception Carrier Screening with Genome Sequencing.

Authors:  Frances L Lynch; Patricia Himes; Marian J Gilmore; Elissa M Morris; Jennifer L Schneider; Tia L Kauffman; Elizabeth Shuster; Jacob A Reiss; John F Dickerson; Michael C Leo; James V Davis; Carmit K McMullen; Benjamin S Wilfond; Katrina A B Goddard
Journal:  J Genet Couns       Date:  2018-02-08       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.